How Investors Are Reacting To Terns Pharmaceuticals (TERN) Promising TERN-701 Phase 1 CARDINAL Data

Simply Wall St.01-16

Terns Pharmaceuticals recently presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, outlining progress across its pipeline programs. Investor attention has centered on ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603193710?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-01-16 04:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603193710","market":"us","top_or_hot":-1,"title":"How Investors Are Reacting To Terns Pharmaceuticals (TERN) Promising TERN-701 Phase 1 CARDINAL Data","media":"Simply Wall St.","content":"<div>\n<p>Terns Pharmaceuticals recently presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, outlining progress across its pipeline programs. Investor attention has centered on ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tern/terns-pharmaceuticals/news/how-investors-are-reacting-to-terns-pharmaceuticals-tern-pro\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Investors Are Reacting To Terns Pharmaceuticals (TERN) Promising TERN-701 Phase 1 CARDINAL Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Investors Are Reacting To Terns Pharmaceuticals (TERN) Promising TERN-701 Phase 1 CARDINAL Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-16 04:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tern/terns-pharmaceuticals/news/how-investors-are-reacting-to-terns-pharmaceuticals-tern-pro><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Terns Pharmaceuticals recently presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, outlining progress across its pipeline programs. Investor attention has centered on ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tern/terns-pharmaceuticals/news/how-investors-are-reacting-to-terns-pharmaceuticals-tern-pro\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TERN.AU","symbol_name":"Terracom Ltd","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tern/terns-pharmaceuticals/news/how-investors-are-reacting-to-terns-pharmaceuticals-tern-pro","article_id":"2603193710","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tern/terns-pharmaceuticals/news/how-investors-are-reacting-to-terns-pharmaceuticals-tern-pro","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2603193710","pubTimestamp":1768509759,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Terns Pharmaceuticals recently presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, outlining progress across its pipeline programs.\nInvestor attention has centered on interim Phase 1 CARDINAL ASH data for TERN-701, which points to a potentially best-in-class profile with encouraging deep molecular responses.\nNext, we’ll examine how the promising TERN-701 Phase 1 CARDINAL data shapes Terns Pharmaceuticals’ investment narrative and future development...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"TERN.AU":"Terracom Ltd","ISBC":"投资者银行","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4007":"制药","BK7083":"煤与消费用燃料","BK4211":"区域性银行","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","TERN":"Terns Pharmaceuticals, Inc."},"translate_title":"投资者对Terns Pharmaceuticals(TERN)承诺的TERN-701一期基本数据有何反应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TERN.AU":1.5,"ISBC":1.5,"TERN":1.5},"content_text":"Terns Pharmaceuticals recently presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, outlining progress across its pipeline programs. Investor attention has centered on interim Phase 1 CARDINAL ASH data for TERN-701, which points to a potentially best-in-class profile with encouraging deep molecular responses. Next, we’ll examine how the promising TERN-701 Phase 1 CARDINAL data shapes Terns Pharmaceuticals’ investment narrative and future development priorities. Uncover the next big thing with financially sound penny stocks that balance risk and reward.AdvertisementWhat Is Terns Pharmaceuticals' Investment Narrative?For Terns Pharmaceuticals, you really have to believe that TERN-701 can anchor the whole story, because this is now effectively a single-asset, clinical-stage bet with no revenue and ongoing losses. The J.P. Morgan presentation and the interim CARDINAL ASH data, framed as potentially best-in-class, look like they reinforce and possibly accelerate the key near-term catalyst: the larger ASH 2025 dataset and clarity on Phase 2/3 planning. That could influence how investors think about the recent US$650,000,000 raise and the earlier equity dilution, shifting the focus from balance sheet risk toward clinical execution risk. At the same time, the intense share price volatility and rich price to book multiple suggest expectations are already high, so any wobble in future CARDINAL readouts or timelines could matter more than before. However, investors should also weigh what happens if TERN-701 data stop matching these early expectations.\n\nOur comprehensive valuation report raises the possibility that Terns Pharmaceuticals is priced higher than what may be justified by its financials.Exploring Other PerspectivesTERN 1-Year Stock Price Chart The Simply Wall St Community’s 2 fair value views for Terns range from US$58.13 to US$98.57, underscoring how far opinions can stretch when a single drug drives the story. That spread sits against a backdrop of heavy recent equity issuance and a highly volatile share price, which together amplify how sensitive the company’s future could be to each CARDINAL update and development milestone.Explore 2 other fair value estimates on Terns Pharmaceuticals - why the stock might be worth over 2x more than the current price!Build Your Own Terns Pharmaceuticals NarrativeDisagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Terns Pharmaceuticals research is our analysis highlighting 1 key reward and 5 important warning signs that could impact your investment decision.Our free Terns Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Terns Pharmaceuticals' overall financial health at a glance.No Opportunity In Terns Pharmaceuticals?Our top stock finds are flying under the radar-for now. Get in early:AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Terns Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603193710","isCrawlerRequest":true}